| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Sales | 16,286 | 16,400 | 17,276 | 15,806 |
| Cost of sales | 4,195 | 5,551 | 3,855 | 3,557 |
| Selling, general and administrative | 2,700 | 2,899 | 2,633 | 2,649 |
| Research and development | 12,592 | 3,886 | 4,234 | 4,048 |
| Restructuring costs | 195 | 213 | 47 | 560 |
| Other (income) expense, net | -138 | -431 | 238 | 7 |
| Total costs, expenses and other | 19,820 | 12,980 | 10,531 | 10,807 |
| (loss) income before taxes | -3,534 | 3,420 | 6,745 | 4,999 |
| Income tax provision | 709 | 457 | 958 | 571 |
| Net (loss) income | -4,243 | 2,963 | 5,787 | 4,428 |
| Less net (loss) income attributable to noncontrolling interests | -3 | 0 | 2 | 1 |
| Net (loss) income attributable to merck & co., inc | -4,240 | 2,963 | 5,785 | 4,427 |
| Basic EPS | -1.72 | 1.195 | 2.32 | 1.76 |
| Diluted EPS | -1.72 | 1.192 | 2.32 | 1.76 |
| Basic Average Shares | 2,472,000,000 | 2,480,000,000 | 2,495,000,000 | 2,510,000,000 |
| Diluted Average Shares | 2,472,000,000 | 2,486,000,000 | 2,498,000,000 | 2,513,000,000 |
Merck & Co., Inc. (MRK)
Merck & Co., Inc. (MRK)